In glioma patients, a relatively large fraction of the CD9+ exosomes were also GFAP-positive (mean = 25.1%); whereas, a small but detectable fraction (mean = 2.9%) of CD9+ exosomes from control individuals had GFAP on their surface (an 8.7-fold difference). This evidence concerns the gene CD9 and glioma.